GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

LLP019   Click here for help

GtoPdb Ligand ID: 13910

Compound class: Synthetic organic
Comment: LLP019 is a PROTAC degrader that targets the 3CL (main) protease (Mpro) of SARS-CoV-2 [1]. It is a heterobifunctional molecule that carries a pelitinib-derived warhead to bind an allosteric site of Mpro, linked to 4-hydroxy-thalidomide to engage the cereblon (CRBN) E3 ubiquitin ligase. LLP019 was designed to allow exploration of the anti-viral potential of selective Mpro degradation.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 17
Hydrogen bond donors 4
Rotatable bonds 20
Topological polar surface area 226.85
Molecular weight 830.22
XLogP -0.57
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC1=CC2=NC=C(C#N)C(=C2C=C1NC(=O)CCOCCOCCNC(=O)COC3=C4C(=CC=C3)C(=O)N(C5CCC(=O)NC5=O)C4=O)NC6=CC=C(C(=C6)Cl)F
Isomeric SMILES CCOC1=CC2=C(C=C1NC(=O)CCOCCOCCNC(=O)COC3=C4C(=O)N(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(NC6=CC=C(F)C(Cl)=C6)=C(C=N2)C#N
InChI InChI=1S/C40H37ClFN7O10/c1-2-58-32-18-28-25(37(22(19-43)20-45-28)46-23-6-7-27(42)26(41)16-23)17-29(32)47-34(51)10-12-56-14-15-57-13-11-44-35(52)21-59-31-5-3-4-24-36(31)40(55)49(39(24)54)30-8-9-33(50)48-38(30)53/h3-7,16-18,20,30H,2,8-15,21H2,1H3,(H,44,52)(H,45,46)(H,47,51)(H,48,50,53)
InChI Key KIUYMPSIESOEAA-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Veeck C, Laube L, Werner A, Diederich W, Becker S. (2025)
Discovery of an Antiviral PROTAC Targeting the SARS-1 CoV-2 Main Protease Using an Allosteric Warhead.
BioRxiv, Preprint. DOI: 10.1101/2025.05.03.652023